ADC Therapeutics Achieves Profitability with ZYNLONTA

ADC Therapeutics ( (ADCT) ) has provided an update.

ADC Therapeutics announced preliminary information on ZYNLONTA’s net sales and expenses for 2024, showcasing stabilized sales despite increased competition and achieving profitability for the brand. The company has implemented a disciplined portfolio management strategy, resulting in a double-digit cost reduction for the second consecutive year, and anticipates a cash runway into mid-2026, positioning itself strongly in the ADC market.

More about ADC Therapeutics

ADC Therapeutics is a commercial-stage company specializing in the development and commercialization of Antibody-Drug Conjugates (ADCs) for the treatment of hematological cancers and solid tumors. The company focuses on expanding its FDA-approved product, ZYNLONTA, while advancing its early-stage portfolio in solid tumors through innovative payloads, linkers, and conjugation chemistry.

YTD Price Performance: -6.00%

Average Trading Volume: 884,815

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $181.8M

Learn more about ADCT stock on TipRanks’ Stock Analysis page.